Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Cao Website

Liang Cao, Ph.D.

Selected Publications

1)  Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G.
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Lancet Oncol. 2014.
2)  Harouaka R, Kang Z, Zheng S, Cao L.
Circulating tumor cells: Advances in isolation and analysis, and challenges for clinical applications.
Pharmacol. Ther. 2013.
3)  Kang Z, Yu Y, Zhu YJ, Davis S, Walker R, Meltzer PS, Helman LJ, Cao L.
Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
Oncogene. 2013.
4)  Kang Z, Sun SY, Cao L.
Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma.
ISRN Oncol. 2012: 395952, 2012.
5)  Kalra N, Zhang J, Yu Y, Ho M, Merino M, Cao L, Hassan R.
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
Int J Cancer. 131: 2143-52, 2012.
6)  Speranza G, Gutierrez ME, Kummar S, Strong JM, Parker RJ, Collins J, Yu Y, Cao L, Murgo AJ, Doroshow JH, Chen A.
Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors.
Cancer Chemother. Pharmacol. 69: 431-8, 2012.
7)  Kang Z, Chen J, Yu Y, Li B, Sun S, Zhang B, Cao L.
Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response.
Clin. Cancer Res. 17: 3181-3192, 2011.
8)  Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, Yu Y, Choyke P, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Kummar S, Gutierrez M, Giaccone G.
Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib.
Clin. Cancer Res. 17: 1190-9, 2011.
9)  Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshow JH.
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Eur. J. Cancer. 47: 997-1005, 2011.
10)  Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado I, Spittler J, Loehrer PJ.
Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors.
J. Clin. Oncol. 29: 2052-9, 2011.
Click Here to View Expanded Bibliography.

This page was last updated on 5/22/2014.